Cory Renauer
Value, research analyst, biotech, small-cap

Infinity Pharmaceuticals And IPI-145: ASCO 2013 Highlights

Advances in crystallography and protein spectroscopy have accelerated the discovery of active sites or "binding pockets" within specific biologic targets. These advances, combined with structure-based drug design, have allowed biotechs to develop highly specific small-molecule inhibitors with far less guesswork, and in turn far smaller budgets.

Blood cancers depend on the dysregulation of key cellular pathways and processes. Improved understanding of those processes and pathways has resulted in an unprecedented number of drugs specifically designed to target them. At the recently concluded American Society of Clinical Oncology (OTC:ASCO) 2013 meeting, investigators presented dozens of studies concerning 11 new drugs developed to combat B-cell malignancies. All 11 were designed to specifically target one of five different proteins involved in...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details